Total Payments
$413,174
2024 Payments
$49,808
Companies
28
Transactions
235
Medicare Patients
1,879
Medicare Billing
$413,130
Payment Breakdown by Category
Consulting$243,968 (59.0%)
Other$93,853 (22.7%)
Travel$55,883 (13.5%)
Research$12,130 (2.9%)
Food & Beverage$7,244 (1.8%)
Gifts$79.42 (0.0%)
Education$15.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $243,968 | 46 | 59.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $70,429 | 18 | 17.0% |
| Travel and Lodging | $55,883 | 69 | 13.5% |
| Honoraria | $15,024 | 4 | 3.6% |
| Unspecified | $12,130 | 4 | 2.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $8,400 | 2 | 2.0% |
| Food and Beverage | $7,244 | 88 | 1.8% |
| Gift | $79.42 | 3 | 0.0% |
| Education | $15.00 | 1 | 0.0% |
Payments by Type
General
$401,044
231 transactions
Research
$12,130
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $56,912 | 42 | $0 (2020) |
| F. Hoffmann-La Roche AG | $55,168 | 27 | $0 (2023) |
| TOPCON MEDICAL SYSTEMS, INC. | $53,656 | 25 | $0 (2023) |
| Boehringer Ingelheim International GmbH | $47,520 | 9 | $0 (2024) |
| Genentech, Inc. | $34,807 | 34 | $0 (2020) |
| Grifols, S.A. | $27,327 | 2 | $0 (2022) |
| TOPCON CORPORATION | $21,315 | 14 | $0 (2023) |
| Novo Nordisk Inc | $19,256 | 13 | $0 (2018) |
| NIDEK CO., LTD. | $18,285 | 6 | $0 (2023) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $17,255 | 5 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $49,808 | 17 | Boehringer Ingelheim International GmbH ($30,224) |
| 2023 | $48,635 | 33 | TOPCON MEDICAL SYSTEMS, INC. ($30,134) |
| 2022 | $17,074 | 3 | TOPCON MEDICAL SYSTEMS, INC. ($15,000) |
| 2021 | $37,923 | 5 | Grifols, S.A. ($27,253) |
| 2020 | $18,531 | 13 | Boehringer Ingelheim International GmbH ($10,006) |
| 2019 | $130,384 | 75 | F. Hoffmann-La Roche AG ($49,842) |
| 2018 | $63,139 | 53 | Novartis Pharmaceuticals Corporation ($15,299) |
| 2017 | $47,679 | 36 | Boehringer Ingelheim Pharma GmbH & Co.KG ($17,255) |
All Payment Transactions
235 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Topcon Healthcare, Inc. | — | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| 10/24/2024 | Alcon Research LLC | — | Consulting Fee | Cash or cash equivalent | $9,500.00 | General |
| 10/24/2024 | Alcon Research LLC | — | Travel and Lodging | Cash or cash equivalent | $60.30 | General |
| 10/24/2024 | Alcon Research LLC | — | Travel and Lodging | Cash or cash equivalent | $60.15 | General |
| 10/10/2024 | Samsung Bioepis Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 10/04/2024 | Alcon Research LLC | — | Travel and Lodging | In-kind items and services | $716.96 | General |
| 10/04/2024 | Alcon Research LLC | — | Travel and Lodging | In-kind items and services | $706.96 | General |
| 10/04/2024 | Alcon Vision LLC | — | Food and Beverage | In-kind items and services | $361.84 | General |
| Category: Ophthalmology | ||||||
| 10/04/2024 | Alcon Vision LLC | — | Travel and Lodging | In-kind items and services | $305.00 | General |
| Category: Ophthalmology | ||||||
| 10/04/2024 | Alcon Vision LLC | — | Travel and Lodging | In-kind items and services | $262.38 | General |
| Category: Ophthalmology | ||||||
| 05/06/2024 | Carl Zeiss Meditec, Inc. | PLEX Elite (Device) | Food and Beverage | In-kind items and services | $95.06 | General |
| Category: Optical Tomographer | ||||||
| 05/06/2024 | Carl Zeiss Meditec, Inc. | PLEX Elite (Device) | Gift | In-kind items and services | $16.05 | General |
| Category: Optical Tomographer | ||||||
| 05/02/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $14,320.00 | General |
| 05/02/2024 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $1,814.58 | General |
| 04/27/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $6,712.00 | General |
| 02/25/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $7,377.20 | General |
| 01/29/2024 | Topcon Healthcare, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| 10/12/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $22.45 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/06/2023 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,680.00 | General |
| 10/06/2023 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $15.82 | General |
| 10/03/2023 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,890.45 | General |
| 05/31/2023 | TOPCON MEDICAL SYSTEMS, INC. | — | Consulting Fee | Cash or cash equivalent | $15,000.00 | General |
| 04/19/2023 | TOPCON MEDICAL SYSTEMS, INC. | — | Travel and Lodging | Cash or cash equivalent | $511.90 | General |
| 04/19/2023 | TOPCON MEDICAL SYSTEMS, INC. | — | Travel and Lodging | Cash or cash equivalent | $297.50 | General |
| 04/04/2023 | TOPCON MEDICAL SYSTEMS, INC. | — | Travel and Lodging | Cash or cash equivalent | $522.50 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Trition OCT-A Pre-Study | TOPCON CORPORATION | $10,423 | 1 |
| A PHASE III, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED, ACTIVE COMPARATOR STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA PAGODA | F. Hoffmann-La Roche AG | $893.78 | 1 |
| STAIRWAY SIMULTANEOUS BLOCKADE OF ANGIOPOIETIN-2 AND VEGF-A WITH THE BISPECIFIC ANTIBODY RO6867461 RG7716 FOR EXTENDED DURABILITY IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | F. Hoffmann-La Roche AG | $619.29 | 1 |
| A PHASE 2, DOUBLE-MASKED, RANDOMIZED, CONTROLLED, MULTIPLE-DOSE, REGIMEN-RANGING STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL REGN2176-3 IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | Regeneron Pharmaceuticals, Inc. | $193.76 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 295 | 458 | $135,862 | $22,585 |
| 2022 | 5 | 382 | 590 | $156,567 | $29,830 |
| 2021 | 7 | 616 | 1,356 | $845,800 | $203,405 |
| 2020 | 6 | 586 | 1,293 | $646,620 | $157,311 |
Total Patients
1,879
Total Services
3,697
Medicare Billing
$413,130
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92014 | Established patient complete exam of visual system | Facility | 2023 | 163 | 191 | $73,012 | $11,138 | 15.3% |
| 67028 | Injection of drug into eye | Facility | 2023 | 39 | 111 | $41,783 | $8,280 | 19.8% |
| 92134 | Imaging of retina | Facility | 2023 | 82 | 144 | $17,801 | $2,689 | 15.1% |
| 92012 | Established patient problem focused exam of visual system | Facility | 2023 | 11 | 12 | $3,266 | $476.96 | 14.6% |
| 92014 | Established patient complete exam of visual system | Facility | 2022 | 102 | 132 | $45,569 | $7,819 | 17.2% |
| 67028 | Injection of drug into eye | Facility | 2022 | 28 | 66 | $24,823 | $4,902 | 19.7% |
| 67028 | Injection of drug into eye | Office | 2022 | 20 | 44 | $28,026 | $4,803 | 17.1% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 52 | 57 | $19,344 | $4,559 | 23.6% |
| 92134 | Imaging of retina | Facility | 2022 | 98 | 161 | $17,817 | $3,208 | 18.0% |
| 92134 | Imaging of retina | Office | 2022 | 59 | 91 | $13,104 | $2,977 | 22.7% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2022 | 11 | 26 | $4,836 | $1,048 | 21.7% |
| 92012 | Established patient problem focused exam of visual system | Facility | 2022 | 12 | 13 | $3,048 | $513.59 | 16.9% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 15 | 178 | $527,948 | $129,885 | 24.6% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 124 | 175 | $57,400 | $17,483 | 30.5% |
| 67028 | Injection of drug into eye | Office | 2021 | 29 | 151 | $95,496 | $16,978 | 17.8% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 124 | 286 | $41,040 | $9,854 | 24.0% |
| 67028 | Injection of drug into eye | Facility | 2021 | 33 | 111 | $39,720 | $8,873 | 22.3% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Facility | 2021 | 100 | 107 | $28,141 | $5,942 | 21.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 44 | 55 | $19,690 | $4,440 | 22.5% |
| 92134 | Diagnostic imaging of retina | Facility | 2021 | 109 | 199 | $16,915 | $4,190 | 24.8% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2021 | 15 | 69 | $12,834 | $3,394 | 26.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 11 | 11 | $3,438 | $1,283 | 37.3% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2021 | 12 | 14 | $3,178 | $1,083 | 34.1% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2020 | 11 | 112 | $332,192 | $83,062 | 25.0% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2020 | 131 | 189 | $61,992 | $19,976 | 32.2% |
About Dr. Nadia Waheed, M.D
Dr. Nadia Waheed, M.D is a Ophthalmology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/06/2005. The National Provider Identifier (NPI) number assigned to this provider is 1245214915.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nadia Waheed, M.D has received a total of $413,174 in payments from pharmaceutical and medical device companies, with $49,808 received in 2024. These payments were reported across 235 transactions from 28 companies. The most common payment nature is "Consulting Fee" ($243,968).
As a Medicare-enrolled provider, Waheed has provided services to 1,879 Medicare beneficiaries, totaling 3,697 services with total Medicare billing of $413,130. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Ophthalmology, Uveitis and Ocular Inflammatory Disease
- Location Boston, MA
- Active Since 12/06/2005
- Last Updated 07/21/2022
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1245214915
Products in Payments
- Non-Covered Product (Drug) $47,893
- Lucentis (Biological) $38,153
- BEOVU (Drug) $37,901
- BROLUCIZUMAB (Drug) $14,491
- OCT-TRITON A (Device) $10,423
- Mirante (Device) $8,500
- Ozempic (Drug) $7,127
- AngioVue (Device) $5,600
- Victoza (Drug) $5,136
- CNTO 2476 (Biological) $4,888
- OCT TRITON (Device) $4,522
- MP-3 (Device) $3,652
- OCT-MAESTRO2 (Device) $2,500
- OCT-MAESTRO (Device) $1,500
- Other (Medical Supply) $1,500
- PLEX Elite 9000 (Device) $567.03
- RTH258A (Drug) $388.39
- EYLEA (Biological) $239.24
- OZURDEX (Drug) $118.76
- CIRRUS HD-OCT (Device) $112.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Boston
Rishi Singh, Md, MD
Ophthalmology — Payments: $2.0M
Ophthalmology $2.0M
Jeffrey Heier
Ophthalmology — Payments: $2.0M
Ophthalmology $2.0M
Bonnie Henderson
Ophthalmology — Payments: $542,042
Ophthalmology $542,042
Dr. Lloyd Aiello, M.d., Ph.d, M.D., PH.D
Ophthalmology — Payments: $284,390
Ophthalmology $284,390
Dean Eliott, Md, MD
Ophthalmology — Payments: $237,285
Ophthalmology $237,285
Jia Yin, M.d., Ph.d, M.D., PH.D
Ophthalmology — Payments: $172,880
Ophthalmology $172,880